Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents : INFORM2 NivEnt

MLA

Cornelis Martinus van Tilburg, et al. Phase I Results of the INFORM2 Combination Study of Nivolumab and Entinostat in Children and Adolescents : INFORM2 NivEnt. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8fee1380240849271857bbb6d8e0f243&authtype=sso&custid=ns315887.

APA

Cornelis Martinus van Tilburg, Melanie Heiss, Ingrid Øra, Andreas Beilken, Uta Dirksen, Nicholas G. Gottardo, Dong-Anh Khuong-Quang, Jordan Hansford, Caroline Hutter, Jasper Van der Lugt, Anne Thorwarth, Isabel Poschke, Inga Harting, Oliver Sedlaczek, Pengbo Beck, Angelika Freitag, David T.W. Jones, Natalie Jäger, Annette Kopp-Schneider, & Olaf Witt. (2022). Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents : INFORM2 NivEnt.

Chicago

Cornelis Martinus van Tilburg, Melanie Heiss, Ingrid Øra, Andreas Beilken, Uta Dirksen, Nicholas G. Gottardo, Dong-Anh Khuong-Quang, et al. 2022. “Phase I Results of the INFORM2 Combination Study of Nivolumab and Entinostat in Children and Adolescents : INFORM2 NivEnt,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8fee1380240849271857bbb6d8e0f243&authtype=sso&custid=ns315887.